Literature DB >> 23269246

The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.

Philip J Vernon1, Tara J Loux, Nicole E Schapiro, Rui Kang, Ravi Muthuswamy, Pawel Kalinski, Daolin Tang, Michael T Lotze, Herbert J Zeh.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) has an aggressive natural history and is resistant to therapy. The receptor for advanced glycation end products (RAGE) is a pattern recognition receptor for many damage-associated molecular pattern molecules. RAGE is overexpressed in both human and murine models of PDA as well as most advanced epithelial neoplasms. The immunosuppressive nature of the PDA microenvironment is facilitated, in part, by the accumulation of regulatory immune cell infiltrates such as myeloid-derived suppressor cells (MDSCs). To study the role of RAGE expression in the setting of mutant Ras-promoted pancreatic carcinogenesis (KC), a triple-transgenic model of spontaneous murine PDA in a RAGE-null background (KCR) was generated. KCR mice had markedly delayed pancreatic carcinogenesis and a significant diminution of MDSCs compared with KC mice at comparable time points postweaning. Although RAGE was not required for the development or suppressor activity of MDSCs, its absence was associated with temporally limited pancreatic neoplasia and altered phenotype and function of the myeloid cells. In lieu of MDSCs, KCR animals at comparable time points exhibited mature CD11b(+)Gr1(-)F4/80(+) cells that were not immunosuppressive in vitro. KCR mice also maintained a significantly less suppressive milieu evidenced by marked decreases in CCL22 in relation to CXCL10 and diminished serum levels of IL-6.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269246      PMCID: PMC4044918          DOI: 10.4049/jimmunol.1201151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Authors:  Minu K Srivastava; Pratima Sinha; Virginia K Clements; Paulo Rodriguez; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 3.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 4.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2010-04-23       Impact factor: 6.968

5.  Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.

Authors:  Shaival H Davé; Jeremy S Tilstra; Katsuyoshi Matsuoka; Fengling Li; Richard A DeMarco; Donna Beer-Stolz; Antonia R Sepulveda; Mitchell P Fink; Michael T Lotze; Scott E Plevy
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

6.  Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.

Authors:  Fanny Chalmin; Sylvain Ladoire; Grégoire Mignot; Julie Vincent; Mélanie Bruchard; Jean-Paul Remy-Martin; Wilfrid Boireau; Alain Rouleau; Benoit Simon; David Lanneau; Aurélie De Thonel; Gabriele Multhoff; Arlette Hamman; François Martin; Bruno Chauffert; Eric Solary; Laurence Zitvogel; Carmen Garrido; Bernhard Ryffel; Christophe Borg; Lionel Apetoh; Cédric Rébé; François Ghiringhelli
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

Review 7.  Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men.

Authors:  Niki A Ottenhof; Anya N A Milne; Folkert H M Morsink; Paul Drillenburg; Fiebo J W Ten Kate; Anirban Maitra; G Johan Offerhaus
Journal:  Arch Pathol Lab Med       Date:  2009-03       Impact factor: 5.534

8.  Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.

Authors:  Michael K Connolly; Jon Mallen-St Clair; Andrea S Bedrosian; Ashim Malhotra; Valery Vera; Junaid Ibrahim; Justin Henning; H Leon Pachter; Dafna Bar-Sagi; Alan B Frey; George Miller
Journal:  J Leukoc Biol       Date:  2009-12-30       Impact factor: 4.962

9.  Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.

Authors:  Erica M Hanson; Virginia K Clements; Pratima Sinha; Dan Ilkovitch; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

10.  The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.

Authors:  R Kang; D Tang; N E Schapiro; K M Livesey; A Farkas; P Loughran; A Bierhaus; M T Lotze; H J Zeh
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

View more
  24 in total

Review 1.  Molecular pathways: myeloid complicity in cancer.

Authors:  Ingunn M Stromnes; Philip D Greenberg; Sunil R Hingorani
Journal:  Clin Cancer Res       Date:  2014-07-21       Impact factor: 12.531

2.  Evaluation of autophagy mediators in myeloid-derived suppressor cells during human tuberculosis.

Authors:  Leigh A Kotze; Vinzeigh N Leukes; Zhuo Fang; Manfred B Lutz; Bryna L Fitzgerald; John Belisle; Andre G Loxton; Gerhard Walzl; Nelita du Plessis
Journal:  Cell Immunol       Date:  2021-08-24       Impact factor: 4.178

Review 3.  The RAGE/multiligand axis: a new actor in tumor biology.

Authors:  Armando Rojas; Ivan Schneider; Cristian Lindner; Ileana Gonzalez; Miguel A Morales
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

4.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Authors:  T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

Review 5.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

6.  Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.

Authors:  Joseph Markowitz; Taylor R Brooks; Megan C Duggan; Bonnie K Paul; Xueliang Pan; Lai Wei; Zachary Abrams; Eric Luedke; Gregory B Lesinski; Bethany Mundy-Bosse; Tanios Bekaii-Saab; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2014-10-11       Impact factor: 6.968

7.  The Dual Role of HMGB1 in Pancreatic Cancer.

Authors:  Rui Kang; Daolin Tang
Journal:  J Pancreatol       Date:  2018-12

8.  The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer.

Authors:  B A Boone; L Orlichenko; N E Schapiro; P Loughran; G C Gianfrate; J T Ellis; A D Singhi; R Kang; D Tang; M T Lotze; H J Zeh
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

9.  Rapid Detection of Neutrophil Oxidative Burst Capacity is Predictive of Whole Blood Cytokine Responses.

Authors:  Philip J Vernon; Leasha J Schaub; Jurandir J Dallelucca; Anthony E Pusateri; Forest R Sheppard
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

10.  The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products.

Authors:  Philip J Vernon; Herbert J Zeh Iii; Michael T Lotze
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.